Revealed: the undisclosed safety data emerging as weedkiller maker faces Parkinson’s lawsuits in US
Source: Guardian Health ↗
Syngenta, the Swiss‑headquartered agrochemical giant that inherited paraquat from its predecessor entities, has been accused of withholding critical safety data from the U.S. Environmental Protection Agency (EPA) as the herbicide remains on the market despite bans in dozens of other nations. Internal corporate records, uncovered through litigation in a Pennsylvania state court, reveal that between 2000 and 2018—when paraquat use in the United States nearly tripled—Syngenta failed to disclose analyses showing how rapidly the chemical can permeate untreated clothing, penetrate skin and enter the bloodstream, and how mixing it with surfactants amplifies absorption. The company also omitted studies indicating severe brain‑related risks, including a potential link to Parkinson’s disease, even though federal law obliges manufacturers to report “unreasonable adverse effects.” While Syngenta promoted a 2016 study that portrayed paraquat as safe, the newly released 3,700‑page dossier demonstrates a systematic effort to keep damaging information from regulators.
The omission of these data comes as global concern over paraquat’s health hazards has intensified. Sweden first called for a ban in 2004, and a cascade of countries followed, including China, which halted domestic use a decade ago after its own safety investigations. In the United States, Vermont and California have recently prohibited paraquat, citing epidemiological research that associates the chemical with Parkinson’s disease, and California regulators announced that manufacturers voluntarily ceased sales after new health‑risk findings. Federal lawmakers have also pressed for a nationwide ban, yet the EPA continues to approve paraquat applications on millions of acres, downplaying the scientific consensus and postponing a promised safety‑review roundtable that never materialized. The internal documents show Syngenta’s strategy of emphasizing favorable research while suppressing evidence of rapid dermal absorption and heightened toxicity when combined with surfactants, tactics that mirror those used to discredit health studies linking the product to chronic illnesses.
The revelations arrive amid a wave of Parkinson’s lawsuits filed by individuals alleging that paraquat exposure caused their disease, with thousands of cases pending nationwide. Although a recent Pennsylvania case was dismissed for insufficient proof of exposure, the litigation has already cost Syngenta at least $187 million in a 2021 settlement, with additional undisclosed payouts for subsequent agreements. Earlier this year the company announced it would cease global production of paraquat, claiming the decision was driven by market considerations rather than health concerns, and it maintains that no link to Parkinson’s exists. Nonetheless, the EPA’s stance that there is no “clear link” between paraquat use and adverse health outcomes remains contentious, especially as other pesticide manufacturers continue to sell the chemical in the United States, raising questions about regulatory oversight and the broader implications for public health policy.
⚡ Effects Interpreter
🌍World Economylow impact
What this means for you
- ▶Trade and investment between countries might shift a touch if things escalate.
- ▶The ripples can spread across borders, nudging growth forecasts here and there.
🏙️Local Economylow impact
What this means for you
- ▶Your local economy has a way of catching these currents eventually.
- ▶Everyday spending habits nearby may shift once the news sinks in.
🏦Rates & Bankslow impact
What this means for you
- ▶Central banks watch moments like this closely, so keep an eye on savings rates.
- ▶The cost of borrowing tends to shift gradually rather than in one leap.
❤️Healthlow impact
What this means for you
- ▶Anyone affected by the risks mentioned might want a word with their GP.
- ▶Vulnerable groups may want extra reassurance from a trusted source.
💷Wealthmedium impact
What this means for you
- ▶The financial side of health news is easy to overlook, but it adds up.
- ▶Days lost to illness can quietly dent household income.
🏠Housinglow impact
What this means for you
- ▶Surveyors and valuers tend to factor in wider trends gradually, not overnight.
- ▶Buyers and renters could notice only a soft drift, if anything at all.
🌍 Effects for your country
The U.S.'s central bank rate currently stands at 3.75%, so a global rates move like this could feed through to local borrowing costs. The U.S.'s economy is growing at 2.3% with inflation at 3.2%, the backdrop this story's effects play out against locally. Housing-market effects like this are usually felt most where mortgage rates track the U.S.'s own central bank rate closely. With the U.S.'s unemployment at 4.4%, personal-finance effects like this land on a labour market that is currently fairly stable. Health-system effects are harder to localise from economic indicators alone — the real impact in the U.S. depends more on local healthcare capacity than the figures above.
The UK's central bank rate currently stands at 3.75%, so a global rates move like this could feed through to local borrowing costs. The UK's economy is growing at 0.8% with inflation at 3.2%, the backdrop this story's effects play out against locally. Housing-market effects like this are usually felt most where mortgage rates track the UK's own central bank rate closely. With the UK's unemployment at 5.6%, personal-finance effects like this land on a labour market that is currently fairly stable. Health-system effects are harder to localise from economic indicators alone — the real impact in the UK depends more on local healthcare capacity than the figures above.
France's central bank rate currently stands at 2%, so a global rates move like this could feed through to local borrowing costs. France's economy is growing at 0.9% with inflation at 1.8%, the backdrop this story's effects play out against locally. Housing-market effects like this are usually felt most where mortgage rates track France's own central bank rate closely. With France's unemployment at 7.9%, personal-finance effects like this land on a labour market that is already under strain. Health-system effects are harder to localise from economic indicators alone — the real impact in France depends more on local healthcare capacity than the figures above.
Romania's central bank rate currently stands at 6.5%, so a global rates move like this could feed through to local borrowing costs. Romania's economy is growing at 0.7% with inflation at 7.8%, the backdrop this story's effects play out against locally. Housing-market effects like this are usually felt most where mortgage rates track Romania's own central bank rate closely. With Romania's unemployment at 6%, personal-finance effects like this land on a labour market that is currently fairly stable. Health-system effects are harder to localise from economic indicators alone — the real impact in Romania depends more on local healthcare capacity than the figures above.
The UAE's central bank rate currently stands at 3.65%, so a global rates move like this could feed through to local borrowing costs. The UAE's economy is growing at 3.1% with inflation at 2.5%, the backdrop this story's effects play out against locally. Housing-market effects like this are usually felt most where mortgage rates track the UAE's own central bank rate closely. Health-system effects are harder to localise from economic indicators alone — the real impact in the UAE depends more on local healthcare capacity than the figures above.